The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Journal article
Judge PK. et al, (2024), Nephrol Dial Transplant
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Journal article
EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
Journal article
ZHU D. et al, (2024), NDT International
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Journal article
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Journal article
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England
Journal article
PESSOA-AMORIM G. et al, (2024), Trials
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Journal article
Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Journal article
Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428
EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY
Journal article
HERRINGTON W., (2024), Clinical and Experimental Nephrology
Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
RECOVERY Collaborative Group None. et al, (2024)
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2023), Lancet Child and Adolescent Health
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article
PETO L. et al, (2023), Nature Communications
Effects of empagliflozin on progression of chronic kidney disease: a pre-specified secondary analysis from the EMPA-KIDNEY trial
Journal article
HAYNES R. et al, (2023), Lancet Diabetes and Endocrinology
Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial
Journal article
Judge P. et al, (2023), Lancet Diabetes and Endocrinology
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Journal article
Wijesurendra RS. et al, (2023), Eur Heart J
Delivering trials in the NHS: more than worth it.
Journal article
Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526